The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis
Open accessPublished version of a preprint
Abstract
The 5-fluorouracil (5-FU)-based chemotherapy regimen is a primary strategy for treating pancreatic cancer (PC). However, challenges related to 5-FU resistance persist. Investigating the mechanisms of 5-FU resistance and identifying a clinically viable therapeutic strategy are crucial for improving the prognosis of PC. Here, through clinical samples analysis, we found that the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme in mevalonate metabolism, is negatively correlated with the efficacy of 5-FU treatment. There is a significant correlation between HMGCR and the pyroptosis marker gasdermin D (GSDMD), and the HMGCR inhibitor simvastatin can significantly inhibit the activation of pyroptosis signaling. The exogenous addition of geranylgeranyl pyrophosphate (GGPP), a key metabolite of the mevalonate pathway, can significantly reduce sensitivity to 5-FU, and simvastatin combined with 5-FU demonstrates a strong synergistic effect. Furthermore, in organoid models and genetically engineered mice with spontaneous PC, the combination of simvastatin and 5-FU significantly inhibits tumor growth. In conclusion, our study reveals the critical role of the mevalonate pathway in 5-FU resistance and proposes a clinically feasible combination therapy strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HMGCR expression may also be relevant, given the inverse association with 5-FU sensitivity”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Xing et al., 2024
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the HMGCR expression is negatively correlated with PDAC sensitivity to 5-fluorouracil (5-FU)”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Xing et al., 2024
The cited source says what the claim attributes to it.
In the citing paper
“the association of simvastatin to 5-FU produces a strong synergistic effect in MIA PaCa-2 line”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Xing et al., 2024
The cited source says what the claim attributes to it.
In the citing paper
“the addition of GGPP, a mevalonate pathway product with a role in prenylation, decreases the 5-FU sensitivity”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Xing et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303 · cited 1×
“Despite recent advances in pancreatic cancer (PC) treatment, it remains a significant challenge, with a 5-year survival rate of less than 10% [1, 2].”
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“…(5-FU) is the cornerstone of the therapeutic protocol, and 5-FU-based FOLFIRINOX is recommended for patients with PC after surgery [3] 0.5-FU, a cell cycle-specific uracil analog, interacts with DNA,RNA, or both, leading to its accumulation in cells, and causing tumor cell damage and death [4].”
InfluentialPyroptosis: A new frontier in cancer
Fang, Y., Tian, S., Pan, Y., Li, W., Wang, Q., Tang, Y., Yu, T., Wu, X., Shi, Y., Ma, P., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109595 · Cited by 1,049
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Huang, B., Song, B.-L., & Xu, C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0174-0 · Cited by 921 · cited 1×
“The mevalonate pathway, a critical pathway for cholesterol synthesis, plays a significant role in tumor progression when abnormally activated [14].”
Pyroptosis in inflammatory diseases and cancer
Rao, Z., Zhu, Y., Yang, P., Chen, Z., Xia, Y., Qiao, C., Liu, W., Deng, H., Li, J., Ning, P., et al. (2022) · Theranostics · doi:10.7150/thno.71086 · Cited by 800
Self-citationSethy, C., & Kundu, C. N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111285 · Cited by 539 · cited 1×
“However, due to the low stability of 5-FU in cells and the susceptibility to drug resistance, only a minority of patients benefit from FOLFIRINOX [7–9].”
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448 · cited 1×
“Despite recent advances in pancreatic cancer (PC) treatment, it remains a significant challenge, with a 5-year survival rate of less than 10% [1, 2].”
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417 · cited 3×
“Simvastatin, in addition to inhibiting cholesterol synthesis, can also target HMGCR and inhibit tumor progression by reducing GGPP and blocking protein prenylation [18, 26, 27].”
Cotte, A. K., Aires, V., Fredon, M., Limagne, E., Derangère, V., Thibaudin, M., Humblin, E., Scagliarini, A., de Barros, J.-P. P., Hillon, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02732-5 · Cited by 359 · cited 1×
“Additionally, the accumulation of lipid droplets and the overexpression of the nuclear protein sterol-regulatory element-binding protein-1 impede the anticancer effect of 5-FU [12, 13].”
Conroy, T., Castan, F., Lopez, A., Turpin, A., Ben Abdelghani, M., Wei, A. C., Mitry, E., Biagi, J. J., Evesque, L., Artru, P., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3829 · Cited by 344
Cited by
Duttenhefner, J. N., & Reindl, K. M. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.06.004 · Cited by 6
“…highlight statin-mediated induction of cellular stress responses, including TME modulation 96 – 99 ] and triggering cellular processes such as autophagy, 100 – 102 ferroptosis, 67,103 ] and pyroptosis, 71 as well as unfolded protein responses linked to enhanced immunogenicity in KRAS mutant tumors.”
Yousaf, S., Ahmed, D. S., Arshad, M., Mammadova, K., Khokhar, A. M., Fawy, K. F., & Rafeeq, H. (2026) · Medical Oncology · doi:10.1007/s12032-026-03239-0 · Cited by 3
Lagunas‐Rangel, F. A. (2026) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100261447016 · Cited by 1
“Several studies have reported synergistic effects when statins are combined with conventional chemotherapeutic agents, such as 5-fl uorouracil (Xing et al., 2024), doxorubicin (Buranrat et al., 2017), cyclophosphamide (Dewidar et al., 2023), and pentoxifylline (Castellanos-Esparza et al., 2018).”
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815366
“HMGCR expression may also be relevant, given the inverse association with 5-FU sensitivity (Xing et al., 2024).”
Zhou, X., Chen, Y., Hua, H., Shen, B., Liang, S., & Hua, D. (2026) · Drug Development Research · doi:10.1002/ddr.70388
Metadata
- Authors
- Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., Li, Z., Zhao, B., Liu, W., Sun, H., & Yu, Z.
- Affiliations
- Lanzhou University Second Hospital (CN)
- Corresponding author
- Yu, Zeyuan
- ORCID
- Venue
- Medical Oncology
- Published
- 2024-11-20
- Volume
- 42
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1357-0560 (ISSN-L)
- 1559-131X
- PMC
- PMC11579105
- OpenAlex
- W4404540456
- Cited by
- 4
- References
- 42
- Citations by year
- 2026: 3 · 2025: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Medical Oncology (publishedVersion, cc-by-nc-nd)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Cuiying Scientific and Technological Innovation Program (CY2022-MS-A05)
- National Natural Sciences Foundation of China (82360601)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mevalonate pathway, 5-fluorouracil resistance, pancreatic cancer, pyroptosis, gasdermin D, HMGCR, simvastatin, geranylgeranyl pyrophosphate, combination therapy, chemotherapy synergy, tumor organoids
- MeSH terms
- Pyroptosis, Animals, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Female, Fluorouracil, Humans, Hydroxymethylglutaryl CoA Reductases, Male, Mevalonic Acid, Pancreatic Neoplasms, Polyisoprenyl Phosphates, Drug Resistance, Neoplasm, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis. https://app.cochat.ai/papers/10.1007/s12032-024-02557-5
- The paper
- Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., Li, Z., Zhao, B., Liu, W., Sun, H., & Yu, Z. (2024). Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis. Medical Oncology. https://doi.org/10.1007/s12032-024-02557-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.